News

RORgamma is a master control switch of immune system activation to treat a broad range of cancers and Lycera has discovered selective and potent oral agonists that target

Exovita Biosciences holds the option to an exclusive, worldwide license for the patent-pending technology developed by Kristina Antonia Trujillo, a research assistant professor in UNM’s Department of Biochemistry

Currently, tesamorelin is not indicated for either of these conditions and the company’s role in this collaboration will include supplying the drug to the MGH. The US National

The company has been developing BB3, which is a proprietary small molecule that mimics the activity of hepatocyte growth factor (HGF). In preclinical models of AKI, BB3 showed

Earlier, the company had announced plans to submit the multi-center, randomized Phase II trial completed last year as one of two pivotal trials required for a new drug

EMDAC voted 13 to 3 that the companies had sufficiently established that the low-density lipoprotein cholesterol (LDL-C) lowering benefit of Praluent exceeds its risks to support approval in

The second successfully out-licensed biosimilar in the product pipeline is ABY-021, which is a humanized monoclonal antibody for treating immunological symptoms. The out-licensing partner is once again a

Advantar’s manufacturing suite includes an ingress/egress area, weighing and dispensing area and equipment clean up area. The manufacturing area and ingress/egress areas are ISO 8 (Class 100,000), HEPA-filtered

Two of these medicines are for the treatment of psoriasis and a third has been accepted for psoriatic arthritis. The other new medicines accepted are the latest of